Most Read

These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative

The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is

The round was led by an undisclosed strategic investor. New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and

The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or

The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer

The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+. The other

McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services. Upon completion of the transaction, Precision Medicine Group will operate under McKesson’s oncology and

This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases. Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances